Nutritional factors in predicting severe myelosuppression during concurrent chemoradiotherapy for esophageal cancer: development and internal validation of a pre-treatment nomogram
- 1Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
- 2Department of Oncology, Bozhou Hospital Affiliated to Anhui Medical University, Bozhou, China
- 3Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
Abstract
Background: Esophageal cancer represents a common form of malignant neoplasm, with concurrent chemoradiotherapy constituting a standard therapeutic approach for locally advanced stages. However, the regimen’s severe adverse effects limit the number of patients who can successfully undergo and complete the treatment. Therefore, this study seeks to examine the relationships between clinical factors and nutritional indicators in relation to myelosuppression during concurrent chemoradiotherapy. Additionally, it aims to develop a robust nomogram prediction model to facilitate early identification and preventive intervention for patients at high risk.
Methods: A retrospective analysis was performed on 200 patients with esophageal cancer, including 198 treated at the Department of Radiotherapy, Fudan University Shanghai Cancer Center, from September 2020 to January 2023 and two treated at The People’s Hospital of Bozhou, Anhui Province, between March 2024 and September 2025. Baseline clinical characteristics and hematological parameters prior to treatment were systematically collected, encompassing tumor stage, age, gender, surgical history, chemotherapy regimen, body mass index (BMI), peripheral blood prealbumin (PA), hemoglobin (Hb), Nutritional Risk Screening 2002 (NRS2002) score, and Prognostic Nutritional Index (PNI). These variables were subsequently subjected to least absolute shrinkage and selection operator (LASSO) regression and multivariate regression analyses to ascertain independent risk factors associated with severe bone marrow suppression (grades 3–4). A nomogram prediction model was developed based on these findings. Model performance was evaluated using discrimination, calibration, and decision curve analysis (DCA), with internal validation performed using 1,000 bootstrap resamples.
Results: The incidence of severe myelosuppression (grades 3–4) among all patients was found to be associated with three independent factors: whether a concurrent TP (paclitaxel or nab-paclitaxel plus cisplatin) regimen is administered, Hb levels, and PNI. A nomogram was developed using the three predictors retained after LASSO selection and multivariable logistic regression: concurrent use of the TP regimen, Hb level, and PNI. The model demonstrated an area under the receiver operating characteristic (ROC) curve of 0.764. Calibration curves indicated a good fit with the standard curve, and DCA revealed substantial clinical benefit for the model at risk thresholds ranging from 0.26 to 0.94.
Conclusions: A pretreatment nomogram for estimating the risk of severe myelosuppression was developed and internally validated using bootstrap resampling. Its generalizability and clinical utility require confirmation in independent external cohorts before clinical application.
Related
- Non-contrast MRI Radiomics Nomogram for Predicting Recurrence and Progression-free Survival in Cervical Cancer following Concurrent Chemoradiotherapy
- Sequential chemoradiotherapy vs. radiotherapy alone or concurrent chemoradiotherapy after radical resection of stage IA2–IIA1 cervical cancer: a retrospective cohort study
- A Systematic Review and Meta-Analysis: Does Molecular Hydrogen Exert Radioprotective Effects Without Compromising the Antitumor Efficacy of Radiotherapy or Concurrent Chemoradiotherapy?
- Comparative Evaluation of Concurrent Carboplatin-Paclitaxel Versus Cisplatin-Etoposide Chemoradiotherapy in Unresectable Non-small Cell Lung Cancer: A Prospective Randomized Study
- Prediction Model for Detecting Active Pulmonary Tuberculosis in Patients With Head and Neck Cancer Prior to Concurrent Chemoradiotherapy
BibTeX
@article{li2026nutritional,
title = {{Nutritional factors in predicting severe myelosuppression during concurrent chemoradiotherapy for esophageal cancer: development and internal validation of a pre-treatment nomogram}},
author = {Zimu Li and Kuaile Zhao and Zhuting Tong},
journal = {Translational Cancer Research},
year = {2026},
month = oct,
doi = {10.21037/tcr-2026-1386},
url = {https://doi.org/10.21037/tcr-2026-1386},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Nutritional factors in predicting severe myelosuppression during concurrent chemoradiotherapy for esophageal cancer: development and internal validation of a pre-treatment nomogram
AU - Zimu Li
AU - Kuaile Zhao
AU - Zhuting Tong
PY - 2026
DA - 2026/10/22
JO - Translational Cancer Research
DO - 10.21037/tcr-2026-1386
UR - https://doi.org/10.21037/tcr-2026-1386
AB - Background: Esophageal cancer represents a common form of malignant neoplasm, with concurrent chemoradiotherapy constituting a standard therapeutic approach for locally advanced stages. However, the regimen’s severe adverse effects limit the number of patients who can successfully undergo and complete the treatment. Therefore, this study seeks to examine the relationships between clinical factors and nutritional indicators in relation to myelosuppression during concurrent chemoradiotherapy. Additionally, it aims to develop a robust nomogram prediction model to facilitate early identification and preventive intervention for patients at high risk. Methods: A retrospective analysis was performed on 200 patients with esophageal cancer, including 198 treated at the Department of Radiotherapy, Fudan University Shanghai Cancer Center, from September 2020 to January 2023 and two treated at The People’s Hospital of Bozhou, Anhui Province, between March 2024 and September 2025. Baseline clinical characteristics and hematological parameters prior to treatment were systematically collected, encompassing tumor stage, age, gender, surgical history, chemotherapy regimen, body mass index (BMI), peripheral blood prealbumin (PA), hemoglobin (Hb), Nutritional Risk Screening 2002 (NRS2002) score, and Prognostic Nutritional Index (PNI). These variables were subsequently subjected to least absolute shrinkage and selection operator (LASSO) regression and multivariate regression analyses to ascertain independent risk factors associated with severe bone marrow suppression (grades 3–4). A nomogram prediction model was developed based on these findings. Model performance was evaluated using discrimination, calibration, and decision curve analysis (DCA), with internal validation performed using 1,000 bootstrap resamples. Results: The incidence of severe myelosuppression (grades 3–4) among all patients was found to be associated with three independent factors: whether a concurrent TP (paclitaxel or nab-paclitaxel plus cisplatin) regimen is administered, Hb levels, and PNI. A nomogram was developed using the three predictors retained after LASSO selection and multivariable logistic regression: concurrent use of the TP regimen, Hb level, and PNI. The model demonstrated an area under the receiver operating characteristic (ROC) curve of 0.764. Calibration curves indicated a good fit with the standard curve, and DCA revealed substantial clinical benefit for the model at risk thresholds ranging from 0.26 to 0.94. Conclusions: A pretreatment nomogram for estimating the risk of severe myelosuppression was developed and internally validated using bootstrap resampling. Its generalizability and clinical utility require confirmation in independent external cohorts before clinical application.
SN - 2218-676X
SN - 2219-6803
ER -